Test Price
2,800 AED✅ Home Collection Available
CALR3 Gene Familial Hypertrophic Cardiomyopathy Type 19 Genetic Test | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
This advanced genetic screening test for the CALR3 gene utilizes Next-Generation Sequencing (NGS) technology to detect pathogenic mutations responsible for Familial Hypertrophic Cardiomyopathy Type 19, achieving a diagnostic accuracy of 99.9%. Performed at our ISO 9001:2015 accredited DHA-licensed facility in Dubai Healthcare City, this test offers comprehensive molecular insights for targeted cardiac risk management.
- ✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing.
- ✔ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✔ Clinical Guidance: Telephonic Post-Test Genetic Counseling for result interpretation.
- ✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CALR3 Genetic Test screens for pathogenic variants linked to familial hypertrophic cardiomyopathy type 19, a condition that may cause life-threatening arrhythmias and sudden cardiac death. Results from this test help guide preventive cardiac care and provide critical information for familial cascade genetic counseling.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | NGS with >99% analytical sensitivity | Sanger sequencing (single gene) |
| Method | Next-Generation Sequencing (Illumina Platform) | Phenotype-limited targeted panel |
| Scope | Full gene sequencing + deletion/duplication analysis | Targeted variant analysis only |
| Turnaround | 3 - 4 Weeks | 4 - 6 Weeks |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specializing in heritable cardiac conditions, I confirm that this NGS-based assay for CALR3 provides a robust foundation for risk stratification. However, genetic findings must always be contextualized within a full cardiological workup, including imaging and family pedigree analysis. A negative result does not completely rule out hypertrophic cardiomyopathy, and a positive result warrants structured cascade screening for at-risk relatives."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403)
Medication Advisory
Patients undergoing genetic evaluation for hypertrophic cardiomyopathy should not discontinue prescribed beta-blockers, calcium channel blockers, or anti-arrhythmic medications without direct consultation with their treating cardiologist. Abrupt cessation of these therapies can precipitate rebound hypertension, tachycardia, or acute heart failure decompensation.
Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: Individuals currently experiencing an acute febrile illness, those unable to provide legally valid informed consent, or patients on high-dose anticoagulant therapy without documented specialist clearance for blood draw.
- Red Flags – Immediate Emergency Care Required: Unexplained syncope (fainting), new-onset exertional chest pain, sustained palpitations accompanied by dizziness or near-syncope, or a documented family history of sudden cardiac death before the age of 40.
Patient FAQ & Clinical Guidance
1. What exactly does the CALR3 gene test detect?
This NGS-based assay sequences the entire coding region and exon-intron boundaries of the CALR3 gene to detect pathogenic or likely-pathogenic variants associated with familial hypertrophic cardiomyopathy type 19. Results are typically reported within 3 to 4 weeks.
2. Is home blood collection available and will it affect sample quality?
Yes, our VIP Mobile Phlebotomy service operates daily from 8 AM to 11 PM. Samples are collected using ISO-certified temperature-controlled cold-chain logistics to ensure complete DNA stability from your home to our laboratory.
3. Should I undergo testing if I am currently asymptomatic?
Yes, current international guidelines support genetic testing for first-degree relatives of individuals with a confirmed pathogenic variant in a cardiomyopathy-associated gene, even in the absence of symptoms. A negative predictive test can alleviate the need for frequent clinical surveillance.
4. How is my genetic data protected under UAE law?
Your genetic data is encrypted end-to-end and processed in strict compliance with UAE Federal Decree-Law No. 45 of 2021 (PDPL). It is stored on secure servers within the UAE and is never shared with third parties without your explicit, written informed consent.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the UAE's comprehensive data protection and healthcare regulatory framework. All genetic data processed through this service is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility (License No. 1143) ensures that your genetic information remains confidential, encrypted, and is never shared without explicit informed consent.
Clinical & Logistical Metadata
| Test Name | CALR3 Gene Familial Hypertrophic Cardiomyopathy Type 19 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 - 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Extracted DNA, or FTA Card Spot |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina Platform |
| ICD-10-CM Code | I42.1, I42.8, Z15.89 |
| LOINC Code | 93680-8 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians